Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766)

N. Chessum(Institute of Cancer Research), Swee Y. Sharp(Institute of Cancer Research), John Caldwell(Institute of Cancer Research), Elisa Pasqua(Institute of Cancer Research), Birgit Wilding(Institute of Cancer Research), Giampiero Colombano(Institute of Cancer Research), Ian Collins(Institute of Cancer Research), Buğra Özer(Institute of Cancer Research), Meirion Richards(Institute of Cancer Research), Martin Rowlands(Institute of Cancer Research), Mark Stubbs(Institute of Cancer Research), Rosemary Burke(Institute of Cancer Research), Craig McAndrew(Institute of Cancer Research), Paul A. Clarke(Institute of Cancer Research), Paul Workman(Institute of Cancer Research), Matthew D. Cheeseman(Institute of Cancer Research), Keith Jones(Institute of Cancer Research)
Journal of Medicinal Chemistry
December 14, 2017
Cited by 93Open Access
Full Text

Abstract

Demonstrating intracellular protein target engagement is an essential step in the development and progression of new chemical probes and potential small molecule therapeutics. However, this can be particularly challenging for poorly studied and noncatalytic proteins, as robust proximal biomarkers are rarely known. To confirm that our recently discovered chemical probe 1 (CCT251236) binds the putative transcription factor regulator pirin in living cells, we developed a heterobifunctional protein degradation probe. Focusing on linker design and physicochemical properties, we generated a highly active probe 16 (CCT367766) in only three iterations, validating our efficient strategy for degradation probe design against nonvalidated protein targets.


Related Papers

No related papers found

Powered by citation graph analysis